Trial Profile
Phase I, Open Label, Clinical Study to Determine the Maximum Tolerated Dose (MTD) of Oral Dovitinib (TKI258) When Given in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma Patients
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 27 Feb 2013
Price :
$35
*
At a glance
- Drugs Dovitinib (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- 19 Feb 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 12 Sep 2012 New trial record